【レポートの概要（一部）】
1. Report Overview
1.1 Global Cholesterol-Lowering Drugs Market Overview
1.2 Global Cholesterol-Lowering Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Cholesterol-Lowering Drugs
2.1 The Pharmaceutical Industry: A Brief Overview
2.2 Cholesterol: An Essential Lipid
2.3 The Functions of Cholesterol
2.4 Metabolism and Circulation of Cholesterol
2.5 The Role of Cholesterol in Heart Disease
2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
2.6.1 The IMPROVE-IT Study
2.7 The Role of Cholesterol in Heart Disease: The Controversy
2.8 Raising HDL Cholesterol: A Worthwhile Aim?
2.9 Causes of Hypercholesterolaemia
2.9.1 Atherosclerosis
2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
2.9.3 Familial Hypercholesterolaemia
2.10 Treatment of Hypercholesterolaemia
2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
2.10.2 US Treatment Guidelines for Hypercholesterolaemia
2.10.3 Lifestyle Changes
2.10.4 Drugs to Lower Cholesterol
2.10.5 Other Therapeutic Approaches
2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
2.11 Classification of Cholesterol-Lowering Drugs
2.11.1 Statins
2.11.2 Selective Cholesterol Absorption Inhibitors
2.11.3 Ion Exchange Resins
2.11.4 Fibrates
2.11.5 Other Cholesterol-Lowering Drugs
2.11.6 Novel Cholesterol-Lowering Drugs
2.11.7 PCSK9 Inhibitors
2.12 Phases of Clinical Trials
2.13 Scope of This Report
2.13.1 Products Excluded from This Report
2.14 Currency Exchange Rates in This Report
3. Cholesterol-Lowering Drugs: World Market 2015-2025
3.1 The World Cholesterol-Lowering Drugs Market in 2014
3.1.1 Leading Cholesterol-Lowering Drugs Products
3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market
3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025
3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025
3.3.1 Cholesterol-Lowering Drugs Market Segmentation
3.4 Changing Market Shares by Segment 2015-2025
3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025
4. Leading National Markets, 2015-2025
4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market
4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025
4.1.2 How Will Regional Market Shares Change to 2025?
4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market
4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025
4.2.2 How Will National Market Shares Change to 2025?
4.3 The US Cholesterol-Lowering Drugs Market 2015-2025
4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025
4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.3.2.1 High Prevalence of High Cholesterol in US
4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025
4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025
4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025
4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025
4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025
4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025
4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments
4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025
4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025
4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.2.1.1 Economic Challenges
4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement
4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025
4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025
4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4.1.1 Lower Oil Prices
4.5.4.1.2 No Embargo on Foreign Drugs
4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025
4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.5.1.1 Drug Price Control Order 2014
4.5.5.1.2 Expansion of Healthcare Provision
4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025
4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments
4.6.1.1 Generic Penetration to Reach 60% by 2018?
4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform
5. Statins and Fixed-Dose Combinations: Market and Pipeline 2015-2025
5.1 Statins: Inhibiting HMG-CoA Reductase
5.2 The Statins and Fixed-Dose Combinations Market in 2014
5.3 Statins and Fixed-Dose Combinations: Market Forecast 2015-2025
5.4 How Will Market Shares of Products Change to 2025?
5.5 Crestor (Rosuvastatin, AstraZeneca)
5.5.1 Crestor: Historical Sales Estimate 2009-2014
5.5.2 Crestor: Sales Forecast 2015-2025
5.5.3 Generic Competition for Crestor
5.6 Lipitor (Atorvastatin, Pfizer)
5.6.1 Lipitor: Historical Sales Estimate 2009-2014
5.6.2 Lipitor: Sales Forecast 2015-2025
5.7 Livalo (Pitavastatin, Kowa)
5.7.1 Livalo: Sales Forecast 2015-2025
5.8 Lescol and Lescol XL (Fluvastatin, Novartis)
5.8.1 Lescol/Lescol XL: Sales Forecast 2015-2025
5.9 Zocor (Simvastatin, Merck)
5.9.1 Zocor: Sales Forecast 2015-2025
5.10 Fixed-Dose Combinations
5.11 Vytorin (Simvastatin/Ezetimibe, Merck)
5.11.1 Vytorin: Sales Forecast 2015-2025
5.12 Caduet (Atorvastatin/Amlodipine, Pfizer)
5.12.1 Caduet: Sales Forecast 2015-2025
6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025
6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview
6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014
6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares of Products Change to 2025?
6.5 Zetia (Ezetimibe, Merck)
6.5.1 The ENHANCE Study: No Additional Benefit
6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk
6.5.3 Zetia: Sales Forecast 2015-2025
6.6 Welchol (Colesevelam, Daiichi Sankyo)
6.6.1 Threat of Imminent Generic Competition for Welchol
6.6.2 Welchol: Sales Forecast 2015-2025
6.7 Tricor (Fenofibrate, AbbVie)
6.7.1 Generic Erosion of Tricor Sales
6.7.2 Tricor: Sales Forecast 2015-2025
7. PCSK9 Inhibitors: Market and Pipeline 2015-2025
7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?
7.2 PCSK9 in Clinical Trials
7.3 PCSK9 Inhibitors and Statins
7.4 PCSK9 Inhibitors: Market Forecast 2015-2025
7.5 How Will Market Shares of Products Change to 2025?
7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025
7.7 Praluent (Alirocumab, Sanofi/Regeneron)
7.7.1 Praluent: Sales Forecast 2015-2025
7.8 Repatha (Evolocumab, Amgen)
7.8.1 GAUSS-2
7.8.2 RUTHERFORD-2
7.8.3 LAPLACE-2
7.8.4 Repatha: Sales Forecast 2015-2025
7.9 RN316 (Bococizumab, Pfizer)
7.9.1 RN316: Sales Forecast 2015-2025
7.10 Oral PCSK9 Inhibitor (Pfizer)
7.11 PF-06427878 (Pfizer)
7.12 PCSK9 Vaccine (Pfizer)
7.13 SX-PCK9 (Serometrix)
7.14 Discontinued Pipeline Products
7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)
7.14.2 LY3015014 (Eli Lilly)
8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025
8.1 Novel Cholesterol-Lowering Drugs: Overview
8.2 Novel Cholesterol-Lowering Drugs Market in 2014
8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025
8.4 How Will Market Shares of Products Change to 2025?
8.5 CETP Inhibitors: Overview
8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025
8.5.2 MK-0859 (Anacetrapib, Merck)
8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025
8.5.3 Dalcetrapib (DalCor)
8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)
8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy’s Laboratories)
8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)
8.5.7 K-312 (CETP Inhibitor, Kowa)
8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025
8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)
8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025
8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025
8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)
8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy
8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025
8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025
8.8.1 K-877 (PPAR-α Agonist, Kowa)
8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)
8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)
8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)
8.9 Discontinued Pipeline Products
8.9.1 Torcetrapib
8.9.2 LY2484595 (Evacetrapib)
9. Leading Companies in the Cholesterol-Lowering Drugs Market
9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014
9.1.1 Leading Companies: Market Forecast 2015-2025
9.1.2 How Will Leading Companies’ Market Shares Change to 2025?
9.2 AstraZeneca
9.2.1 AstraZeneca: Cholesterol-Lowering Drugs
9.2.2 AstraZeneca: Sales Forecast 2015-2025
9.2.3 AstraZeneca: Recent Developments
9.2.3.1 Cholesterol Awareness Initiative in America
9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid
9.3 Merck
9.3.1 Merck: Cholesterol-Lowering Drugs
9.3.2 Merck: Sales Forecast 2015-2025
9.3.3 Merck: Recent Developments
9.3.3.1 Bayer Acquires Merck’s Consumer Health Business
9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial
9.4 Pfizer
9.4.1 Pfizer: Cholesterol-Lowering Drugs
9.4.2 Pfizer: Sales Forecast 2015-2025
9.4.3 Pfizer: Recent Developments
9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program
9.4.3.2 Development of Oral PCSK9 Inhibitor
9.5 Kowa
9.5.1 Kowa: Cholesterol-Lowering Drugs
9.5.2 Kowa: Sales Forecast 2015-2025
9.5.3 Kowa: Recent Developments
9.5.3.1 Development of K-312
9.5.3.2 Development of K-887
9.6 Daiichi Sankyo
9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs
9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025
9.6.3 Daiichi Sankyo: Recent Developments
9.6.3.1 Staff Reduction at US Operation
9.7 AbbVie
9.7.1 AbbVie: Cholesterol-Lowering Drugs
9.7.2 AbbVie: Sales Forecast 2015-2025
9.7.3 AbbVie: Recent Developments
9.7.3.1 Possible Marketing Cost Reductions
9.8 Novartis
9.8.1 Novartis: Cholesterol-Lowering Drugs
9.8.2 Novartis: Sales Forecast 2015-2025
9.9 Sanofi
9.9.1 Sanofi: Cholesterol-Lowering Drugs
9.9.2 Sanofi: Sales Forecast 2015-2025
9.9.3 Sanofi: Recent Developments
9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals
9.10 Amgen
9.10.1 Amgen: Cholesterol-Lowering Drugs
9.10.2 Amgen: Sales Forecast 2015-2025
9.10.3 Amgen: Recent Developments
9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent
10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025
10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market
10.2 Strengths
10.2.1 Strong Pipeline
10.2.2 High Profile Encouraging Healthcare Provision
10.3 Weaknesses
10.3.1 Increasing Generic Penetration
10.3.2 Approved Indications Limited for New Products
10.4 Opportunities
10.4.1 Increasing Prevalence in Emerging Markets
10.4.2 Possible Additional Indications
10.5 Threats
10.5.1 Patent Expiry
10.5.2 Cost-Containment
10.6 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market
10.6.1 Rivalry among Competitors [High]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Low]
10.6.4 Power of Buyers [Medium]
10.6.5 Threat of Substitutes [High]
11. Conclusions
11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015
11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025
12. Glossary
【レポート販売概要】
■ タイトル：コレステロール低下剤の世界市場：PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト■ 英文：Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
■ 発行日：2015年11月
■ 調査会社：visiongain
■ 商品コード：VGAIN5112512
■ 調査対象地域：グローバル
- 自動車用アンチピンチ機能付パワーウィンドウ装置の世界市場2017-2021About Automotive Anti-Pinch Power Window System Anti-pinch power window systems are safety features fitted in vehicles to prevent anything from getting stuck in a closing window. The power window has many advanced features that make it user-friendly, such as the single-press switch. However, although it offers advantages like ease-of-use to the passenger and driver, it can cause harm if it traps a …
- Humira（クローン病治療薬）：市場予測及び分析（～2022）Humira (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and …
- 世界の兵士現代化市場：競争状況及び戦略的インサイトSummary This report shows the leading Soldier Modernization market segments in various regions across the world. Details of top companies active across the global Soldier Modernization market are provided, together with market size and forecast 2015-2025 for the main players across those areas. Key Findings The report provides a detailed analysis of the competitive landscape of the Soldier Moderni …
- 世界の小型自動車用電子制御ブレーキング市場【2015年1月更新版】This latest just-auto report edition offers a global review of the OE electronic braking sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE electronic braking market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategi …
- グローバル防衛市場の景況感レポート（2014年Q2）Summary “Defense Business Confidence Report Q2 2014” is a new report by Strategic Defence Intelligence that globally analyzes industry opinions on the latest economic and customer issues, and their impact on investment decisions and growth prospects within the defense industry. This report also examines executive opinion about the current and future state of the economy and its retrospective effec …
- 2014年戦略提言：スペインの呼吸器病診断検査市場About This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the Spanish Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. …
- B型肝炎およびC型肝炎検査の世界市場2016-2020About Hepatitis B and Hepatitis C Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid …
- モバイルプロジェクターの世界市場2017-2021About Pico ProjectorsPico projector is used to project images through a handheld device. These projectors are embedded into several devices, such as smartphones and cameras, and is popular as pico projectors. These are miniature image, video, image, or personal digital assistant (PDA) projectors and are used for several applications such as projecting information on relatively large screens. Techn …
- 世界のトップ10コネクテッド/スマート産業“Growing need for operational efficiency drives the top 10 connected/smart industries”The top 10 connected/smart industries are estimated to grow at a significant rate during its forecast period. This report covers large aspects of the connected technologies implemented in different industries. Emergence of IoT technology, need for cost efficient technology solutions, and increasing adoption of co …
- 表面検査の世界市場：カメラ、フレーム取り込み装置、光学、照明装置、プロセッサ、ソフトウェアThe surface inspection market was valued at USD 2.02 Billion in 2015 and is expected to grow at a CAGR of 7.9% between 2016 and 2022. The market growth can be directly linked with the growth of the manufacturing industry. Increasing demand for quality from manufacturers and customers has made vision-based surface inspection the key technology in the area of manufacturing and quality control. Recen …
- 2014年戦略提言：アメリカの病院内感染症検査市場This new report from Venture Planning Group contains 997 pages, 87 tables, and presents a comprehensive analysis of the US hospital infectious disease testing market, including: Major issues pertaining to the US hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Current …
- デング熱(Dengue)：世界の治験レビュー（2015年上半期版）Dengue Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Dengue Global Clinical Trials Review, H1, 2015" provides data on the Dengue clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dengue. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction ac …
- 死角検知 （BSD）システムの世界市場2015-2019Technavio research analysts predict a market growth rate of over 21% from 2015 to 2019. Recent advances in technology in the global automobile market have augmented the position and importance of safety systems in the market. Analysts expect the demand for automotive blind spot detection to grow considerably during the forecast period. This market is driven by an increasing emphasis on safety solu …
- ビックデータ分野のリーディング企業分析：InformaticaBig Data represents a collection of data sets so large and complex that it becomes difficult to process using on-hand database management tool. It is also unstructured, meaning that it is not tabulated, correlated, etc. (e.g. it does not have a pre-defined data model or is not organized in a pre-defined manner). Big Data technologies enable organizations to handle huge datasets and generate inform …
- 世界のヘルスケアIT市場動向（2012-2016）TechNavio's analysts forecast the Global Healthcare IT market to grow at a CAGR of 5.3 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing need to store patient information and use it to provide appropriate/better healthcare services. The Global Healthcare IT market has also been witnessing the increased application of mobile technology. H …
